HS Code:
Rutoside, also known as Rutin, and its derivatives fall under the category of flavonoids, which are naturally occurring compounds found in plants. Rutin is commonly used in the pharmaceutical and nutraceutical industries for its antioxidant, anti-inflammatory, and vasoprotective properties. It is often incorporated into dietary supplements, cosmetics, and medicines aimed at improving vascular health and reducing inflammation. The global trade of Rutoside and its derivatives is driven by demand in health and wellness sectors, with significant production tied to the availability of raw materials like citrus fruits and buckwheat.
Total Trade Volume
Approximately $150 million USD
Data from 2022
Source
UN Comtrade Database and International Trade Centre (ITC)
$60 million USD
40% of total trade of total trade
Increasing
$30 million USD
20% of total trade of total trade
Increasing
$25 million USD
17% of total trade of total trade
Stable
$15 million USD
10% of total trade of total trade
Stable
$10 million USD
7% of total trade of total trade
Decreasing
Average Rate
5.2% ad valorem
Highest Rate
12% (applied by certain developing countries)
Lowest Rate
0% (under free trade agreements like EU-Japan EPA)
Rising demand for natural antioxidants
Increased export volumes from countries with abundant raw material sources like China and India, boosting trade by 15% annually
2021-2022
Shift towards plant-based supplements
Growing consumer preference for natural health products has driven a 10% increase in demand for Rutin-based supplements
2020-2022
Technological advancements in extraction
Improved extraction techniques have reduced production costs by 8%, making Rutin more competitive in global markets
2019-2022
The European Union introduced stricter guidelines on the importation of flavonoid compounds, including Rutin, requiring detailed documentation on sourcing and purity.
March 2023
Potential delays in shipments and increased compliance costs for exporters, particularly from Asia, estimated to affect 20% of trade volume to the EU.
A revised trade agreement between the US and China included reduced tariffs on certain pharmaceutical raw materials, including Rutin derivatives.
January 2023
Expected to increase Chinese exports to the US by 10% over the next two years, strengthening China's position as the top exporter.
A German research institute developed a novel synthetic method for producing Rutin derivatives, potentially reducing reliance on natural sources.
September 2022
Could disrupt traditional supply chains if scaled commercially, impacting exporters like China and India in the long term.